About: Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $23.50 (-3.21%)
NGNE NASDAQ Neurogene Inc
Neurogene Inc share price
Atividade de preço de NGNE
Último preço
$ 23,500
Variação (24h)
-0,78 USD (3,21%)
Volume
55.49K
Volume (média 4 sem.)
-
Abertura
$ 24,11
Variação do dia
$ 23,08 - $ 24,11
Fechamento anterior
$ 24,28
Último negócio
23 Oct, 5:18 pm GMT+0
Atrasado
23 Oct, 5:18 pm GMT+0
NGNE price performance
Atrasado
23 Oct, 5:18 pm GMT+0
quote.marketSignals